All News

The designation, which will expedite the development and review of sacituzumab govitecan in TNBC, is based on a phase 2 trial in which the therapy induced a response rate of 31 percent in heavily pretreated patients with metastatic TNBC.

It should be no surprise that it took someone whose life was deeply impacted by the cancer experience to finally create a shift in how we approach a cure for this illness.

"No recent cancer advance has been more transformative than immunotherapy," said ASCO president Julie M. Vose.

In an interview with CURE, Philippe Moreau discusses the significance of Ninlaro's approval and the TOURMALINE-MM1 study.

Giving cancer any type of credit is like entering a forbidden city, but maybe somewhere in there, cancer can in fact lead us to some positives in our lives.

Held each year on Feb. 4, World Cancer Day aims to unite people from around the world to increase awareness of cancer in a positive and inspiring way.

The approval is primarily based on the phase 3 MK-0517-031 study, in which adding single-dose Emend for injection induced a complete response in nearly 80 percent of patients receiving MEC.

Cancer does not mean a death sentence. Many of us are walking around, living life with cancer.

Cometriq elicited a statistically significant improvement in survival compared with Afinitor as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.

Learning to accept my body after a double mastectomy.

To better understand the implications of the expanded approval and the potential for Opdivo, we spoke to Jedd D. Wolchok from Memorial Sloan Kettering Cancer Center.

A breast cancer and melanoma survivor ponders her relationship with her body several years after diagnoses.

The designation is based on data from the phase 2 TOPARP-A trial that demonstrated that Lynparza monotherapy had an overall response rate of nearly 90 percent in a biomarker-defined subgroup of patients who had DNA-repair defects.

Cancer and the blues go together like chemotherapy and hair loss.

Living through illness is never easy. It is so tempting to let diseases and diagnoses take our energy and make us bystanders in our own lives. But if every day of our life — even when full of suffering — is an adventure to be lived, how can we be a part of it? Because we must be a part of it.

"Our latest study is the first to demonstrate that blocking or deleting the A2A receptor can be useful in reducing radiation-induced scarring in skin," Bruce Cronstein said.

These data were presented in mid-December 2015.

The study was stopped early after an independent monitoring panel determined the primary endpoint of improvement in OS was met.

A legendary cornerback in the NFL, former New England Patriots and Los Angeles Raiders star Mike Haynes is no stranger to going to battle on the gridiron.

Reflections on the wonders — and the hierarchy — of modern hospital care.

Following doctors orders is what we're supposed to do, but sometimes it's a personal choice.

The approval of Halaven was based on an improvement in overall survival (OS) in a phase 3 study.

Despite the fact that it has been three years since the drug was approved by the FDA, many oncologists still need to be educated regarding Xofigo's benefits beyond pain palliation,

A breast cancer and melanoma survivor reflects on being tired of her cancers and living with uncertainty.

Results from new clinical trials signal a role for the immunotherapy Opdivo in the treatment of gastric cancer and heavily pretreated esophageal cancer.

Exercise, protein, belief and visualization are my not-so-secret weapons in my life with metastatic breast cancer.

How I use the law of attraction to take back control of my mental, emotional and spiritual health.

To gain insight into the methodology and impacts of this research, CURE interviewed Joan H. Schiller, an author on the study.